

Test Patient (Test Jia En) 1234_____

Date: 16 August 2023

HEALTH SCREENING REPORT

For further enquiries, please email to EAC@parkwaypantai.com



KEY RECOMMENDATIONS

Recon	nmendations	Follow-up
¢	Systolic Blood Pressure High: 140 [100 - 129 mmHg]	• Your blood pressure is elevated. You are advised to consult with our doctors for further evaluation of your blood pressure. Persistent high blood pressure requires long-term drug treatment to prevent endorgan damage to the arteries, kidneys, eyes, heart and brain. Reduce salt intake, adopt lifestyle and dietary modifications. You may contact our clinic for dietetics services. Treatment with anti-hypertension drug is advised if the repeated blood pressures remain elevated.





This is the end of your health report.

Examining Doctor	Dr Petty Chen
Reporting Doctor	Dr Petty Chen
Date	16 August 2023




3

EXECUTIVE SUMMARY



BLOOD PRESSURE 140 / 60 mmHg





MEDICAL AND FAMILIAL HISTORY

Your health report takes into account the following information you provided during your health screening:


Your Demographics Age: 30 Gender: Female Ethnicity: Chinese

Drug Allergies NKDA

Medical History

Family History Father: Stroke





HEAD & NECK



Eyes:

Ears:

Oral Cavity: Thyroid Gland: LNS:

Normal. Pupils equal and reactive to light. Extraocular movement normal Normal. External auditory canals clear. Tympanic membranes intact Normal Normal

CHEST, HEART & LUNGS

Breasts: Respiratory System: Cardiovascular System:

Normal Normal Normal. S1S2 no murmurs

BONE & NERVOUS SYSTEM

d b		
	eural System:	Normal
• О М	lusculoskeletal System:	Normal

ABDOMEN & PELVIS



Abdomen: Female Genitalia: Normal Normal



PANEL

BP and Biometrics

Systolic Blood Pressure

Low	Normal	Borde	arline	High	
LOW	100	130	150	mgn	

CLINICAL & LABORATORY FINDINGS

O (Your result: 140.0 mmHg)



APPENDIX

CARDIAC-ASSOCIATED RISK ASSESSMENT

Your estimated prognosis of coronary artery disease risk in 10 years is close to the national average. The national average risk for females in your age group is 1%.


SUGGESTED LIFESTYLE ADJUSTMENTS

Currently, your **Coronary Artery Disease Risk in 10 Years** prognosis is comparable to or better than the population average. This suggests that your current life style is sufficient to maintain this risk at relatively low levels. However, the following changes are suggested according to clinical practice guidelines.

Risk Contributor	Current read- ing	Target value	Units
Systolic Blood Pressure	140	<130	mmHg
Coronary Artery Disease Risk in 10 Years	<1 %	<1 %	

ALTERNATIVE RISK SCENARIOS

Below we present the estimated dynamics of the risk, based on extrapolation of the observed trends in the parameters in the next 10 years. Following the doctor's recommendations may reverse the negative trend and decrease future risks.



Coronary Artery Disease Risk Assessment ⁴ technical information:

Coronary Artery Disease (CAD) describe events affecting the blood vessels and the heart. Some common examples of such events include coronary heart disease, cerebrovascular disease, peripheral vascular disease and stroke. The risk of CAD is predicted using an algorithm adapted to Singaporean population from the Framingham Heart Study that takes into account age, total and high-density lipoprotein cholesterol, systolic blood pressure, treatment for hypertension, smoking, and diabetes status to predict the risk of developing any CAD in the next 10 years.



DISCLAIMER AND ADVISORIES

- 1. Regular comprehensive health screening will enable early detection of chronic diseases in particular- diabetes, hypertension, cardiovascular diseases, cancers, liver, kidney, thyroid diseases and osteoporosis and enable early treatment to prevent complications.
- 2. Health screening may have both false positive and false negative results and may not pick up all occult diseases. Any abnormal finding may need further investigations or a referral to a Specialist.
- 3. Tumour markers are of limited value and are not advised to be used for the diagnosis of cancer on their own. Tumour markers are produced by cancer or by other cells of the body in response to cancer or certain benign (non-cancerous) conditions. Further investigations may be necessary if the tumour markers are elevated.
- 4. The treadmill stress test is only 60-70% accurate in detecting coronary artery disease. False positive results may occur and may need further evaluation.
- 5. A Screening Colonoscopy is advised once you reach the age of 50 or earlier if there is family history of colo-rectal cancer.
- 6. Please consult our doctors with regards to skin cancer screening.
- 7. Regular breast examination is advised with age-appropriate screening tests or if advised by your doctor.
- 8. Please note that the current MOH recommendations state: All women who have ever had sexual intercourse are advised to undergo screening for cervical cancer from the age of 25. Women aged 25 to 29 years are advised to be screened with the Pap smear, at least once every 3 years. Women aged 30 years and above are advised to be screened with HPV testing. This are advised to be performed at least once every 5 years.

REFERENCES

- 1. Ministry of Health. National Population Health Survey 2016/17. MOH Singapore, 2018. https://www.moh.gov.sg/ resources-statistics/reports/national-population-health-survey-2016-17.
- 2. Ministry of Health. National Health Survey 2010. MOH Singapore, 2011. https://www.moh.gov.sg/resources-statistics/ reports/national-health-survey-2010.
- 3. Loh TP, Ma S, Heng D, Khoo CM. Age-Related Changes in the Cardiometabolic Profiles in Singapore Resident Adult Population: Findings from the National Health Survey 2010. 2016 PLOS ONE 11(8): e0162102. https://doi.org/10.1371/ journal.pone.0162102
- 4. Tai ES, Chia BL, Bastian AC, et al. Ministry of Health Clinical Practice Guidelines: Lipids. Singapore Med J. 2017 Mar;58(3):155-166.
- 5. Goh SY, Ang SB, Bee YM, et al. Ministry of Health Clinical Practice Guidelines: Diabetes Mellitus. Singapore Med J. 2014 Jun;55(6):334-47.
- 6. Tay JC, Sule AA, Chew EK, et al. Ministry of Health Clinical Practice Guidelines: Hypertension. Singapore Med J. 2018 Jan;59(1):17-27.
- 7. Cervical Screen Singapore Advisory Committee, Health Promotion Board. Management Guidelines for Cervical Screening & Preinvasive Disease of the Cervix. Singapore 2019. https://www.sccps.org/wp-content/uploads/2019/03/CSS-Clinical-Mgt-Guidelines-2019_March-Release.pdf

THE PRODUCT AND CONTENT ARE PROVIDED ON AN "AS IS" BASIS. MESH BIO EXPRESSLY DISCLAIM ALL WARRANTIES OF ANY KIND WITH RESPECT TO THE PRODUCT OR CONTENT, WHETHER EXPRESS OR IMPLIED, INCLUDING IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESSS FOR A PARTICULAR PURPOSE, TITLE AND NON-INFRINGEMENT. MESH BIO MAKES NO WARRANTY THAT THE PRODUCT AND/OR ANY CONTENT THEREIN WILL MEET YOUR REQUIREMENTS, OR WILL BE UNINTERRUPTED, TIMELY, SECURE, CURRENT, ACCURATE, COMPLETE OR ERROR-FREE OR THE RESULTS MAY BE OBTAINED BY USE OF THE PRODUCT OR ANY CONTENT THEREIN WILL BE ACCURATE OR RELIABLE. YOU UNDERSTAND AND ACKNOWLEDGE THAT YOUR SOLE AND EXCLUSIVE REMEDY WITH RESPECT TO ANY DEFECT IN OR DISSACTISFACTION WITH THE PRODUCT IS TO CEASE ITS USE.

THE CONTENT ON THE PRODUCT IS PRESENTED AS AN EDUCATIONAL SERVICE INTENDED FOR LICENSED HEALTHCARE PROFESSIONALS. WHILE THE CONTENT IN THE PRODUCT IS ABOUT SPECIFIC MEDICAL AND HEALTHCARE ISSUES, THE CONTENT IS NOT A SUBSTITUTE FOR, OR REPLACEMENT OF PERSONALIZED MEDICAL ADVICE AND IS NOT INTENDED TO BE USED AS THE SOLE BASES FOR MAKING INDIVIDUALIZED MEDICAL OR HEALTH RELATED DECISIONS.

THE CONTENTS PROVIDED BY THE PRODUCT ARE SOLELY BASED ON PUBLISHED CLINICAL STUDIES AND CLINICAL GUIDELINES, AND DO NOT REPRESENT A MESH BIO ENDORSEMENT OR EVALUATION OF THESE STUDIES. THE CONTENT ON THE PRODUCT IS NOT INTENDED TO PRESENT THE ONLY, OR NECESSARILY THE BEST, METHODS, OR PROCEDURES FOR THE MEDICAL SITUATIONS ADDRESSED. ANY REFERENCE TO A SPECIFIC THERAPY OR COMMERCIAL PRODUCT OR SERVICE IN THIS PRODUCT DOES NOT CONSTITUTE A GUARANTEE OR ENDORSEMENT BY MESH BIO OF THE QUALITY OR VALUE OF SUCH A THERAPY OR PRODUCT OR SERVICE OR ANY CLAIMS MADE BY THE MANUFACTURER OR PROVIDER OF SUCH THERAPY OR COMMERCIAL PRODUCT OR SERVICE.

Copyright 2018-2023 Mesh Bio Pte. Ltd. All rights reserved